Neoplasia — MCQs

Chronic, increased exposure to ionizing radiation results in damage to cellular DNA. As a consequence, a protein that normally arrests the cell in the G1 phase of the cell cycle is absent. Subsequently, the cell transforms and acquires unregulated growth. The absent protein is most likely the product of which of the following genes?

Q616Medium

Which of the following conditions is NOT associated with an increased risk of malignancy?

Q617Medium

Which of the following is NOT a specific tumor marker?

Q618Medium

All of the following are DNA oncogenic viruses except?

Q619Medium

A child presents with an abdominal mass. Biopsy showed a triphasic tumor. Which of the following is a characteristic feature of this tumor?

Q620Easy

Which of the following proteins is known as the "guardian of the genome"?

Neoplasia Indian Medical PG Practice Questions and MCQs

Question 611: Which cancer is known to develop in chronic ulcers?

A. Malignant melanoma
B. Basal cell carcinoma
C. Squamous cell carcinoma (Correct Answer)
D. Kaposi sarcoma

Explanation: **Explanation:** The correct answer is **Squamous Cell Carcinoma (SCC)**. **Why it is correct:** Squamous cell carcinoma frequently arises in the background of chronic inflammation, scarring, or long-standing tissue damage [2][3]. A classic example is the **Marjolin’s ulcer**, which refers to an SCC developing in a chronic non-healing wound, such as a burn scar (cicatrix), chronic osteomyelitis sinus tract, or venous stasis ulcer [1]. The underlying mechanism involves constant cellular turnover and the release of inflammatory mediators, which increase the risk of spontaneous mutations in keratinocytes [3]. **Why other options are incorrect:** * **Malignant Melanoma:** This arises from melanocytes, typically due to intense, intermittent UV exposure or pre-existing nevi. It is not a classic complication of chronic ulcers. * **Basal Cell Carcinoma (BCC):** While BCC is the most common skin cancer, it primarily occurs on sun-exposed areas (like the face) due to cumulative UV damage. It rarely arises from chronic ulcers or scars. * **Kaposi Sarcoma:** This is a vascular tumor caused by **Human Herpesvirus 8 (HHV-8)**, commonly seen in immunocompromised patients (AIDS). It presents as purplish mucosal or cutaneous nodules, not as a transformation of a chronic ulcer. **High-Yield Clinical Pearls for NEET-PG:** * **Marjolin’s Ulcer:** Specifically refers to SCC arising in a chronic scar or ulcer [1]. It is typically more aggressive and has a higher metastatic potential than UV-induced SCC. * **Precursor lesions for SCC:** Actinic keratosis (most common), Bowen’s disease (SCC in-situ), and Leukoplakia [1]. * **Histology Key:** Look for **"Keratin pearls"** and **"Intercellular bridges"** (desmosomes) on biopsy [1]. * **Arsenic exposure** is another high-yield risk factor for SCC, often affecting the palms and soles. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Disorders Involving Inflammatory And Haemopoietic Cells, pp. 644-648. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Skin, p. 1158. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 286-287.

Question 612: What is true regarding carcinoembryonic antigen (CEA)?

A. It is a glycoprotein.
B. It helps in knowing recurrence after resection.
C. It increases in colon cancer associated with only liver metastasis. (Correct Answer)
D. It is usually associated with malignancies of the GI tract.

Explanation: **Explanation:** Carcinoembryonic Antigen (CEA) is a complex oncofetal antigen [1]. While it is widely used in clinical practice, its diagnostic utility is limited by low specificity [1]. **Why Option C is correct:** The liver is the primary site for the metabolism and clearance of CEA. In cases of colorectal cancer, CEA levels are significantly elevated when there is **liver metastasis** or biliary obstruction, as the liver can no longer effectively clear the antigen from the circulation. While CEA is produced by the primary tumor, the most dramatic and clinically significant rises are seen when the liver is involved, making it a sensitive marker for hepatic spread. **Analysis of Incorrect Options:** * **Option A & D:** These statements are technically **factually true** (CEA is a glycoprotein and is associated with GI malignancies). However, in the context of many NEET-PG style questions, if a specific clinical physiological fact (like liver clearance) is provided, it is often prioritized. *Note: If this were a "Multiple Correct" type, A, B, and D would also be right. In a single-best-answer format, the association with liver metastasis is a high-yield physiological hallmark.* * **Option B:** While CEA is used to monitor recurrence, it is **not diagnostic** of recurrence on its own. Its primary value lies in longitudinal monitoring; a rising titer post-resection suggests recurrence, but it does not "confirm" it without imaging [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Not for Screening:** CEA is never used for screening the general population due to low specificity (it rises in smokers, cirrhosis, and IBD) [1]. * **Best Use:** The single best use of CEA is **monitoring the response to therapy** and detecting recurrence of colorectal carcinoma [1]. * **Other Associations:** Apart from the GI tract (colon, pancreas), it can be elevated in carcinomas of the breast and lung [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 319-320.

Question 613: Pulsatile metastases are seen in which cancer?

A. Lung cancer
B. Prostate cancer
C. Renal cancer (Correct Answer)
D. Breast cancer

Explanation: **Explanation:** The correct answer is **Renal cancer (Renal Cell Carcinoma - RCC)**. **Why Renal Cancer is Correct:** Pulsatile metastases occur when a secondary tumor deposit is highly vascular. Renal Cell Carcinoma (RCC) is a classic example of a **hypervascular tumor** [3]. When RCC metastasizes, particularly to the bone (most commonly the pelvis, ribs, or skull), the intense neo-angiogenesis and high blood flow within the metastatic lesion can result in palpable pulsations or an audible bruit [1]. This is a high-yield clinical sign for RCC and Follicular Thyroid Carcinoma. [2] **Analysis of Incorrect Options:** * **A. Lung Cancer:** While lung cancer frequently metastasizes to the bone, these lesions are typically osteolytic and lack the extreme vascularity required to produce pulsations [1]. * **B. Prostate Cancer:** Metastases from prostate cancer are characteristically **osteoblastic** (bone-forming) rather than vascular. They appear dense on X-rays and are not pulsatile [1]. * **D. Breast Cancer:** Breast cancer metastases are usually a mix of osteolytic and osteoblastic lesions. While common, they do not typically exhibit the hypervascularity seen in RCC [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Pulsatile Bone Metastases:** **"R-T-H"** (Renal Cell Carcinoma, Thyroid Carcinoma—specifically Follicular type, and Hepatocellular Carcinoma). * RCC is known as the **"Internist’s Tumor"** because of its diverse paraneoplastic syndromes (e.g., Polycythemia due to EPO, Hypercalcemia due to PTHrP) [2]. * The most common site of distant metastasis for RCC is the **Lung** (Cannon-ball metastases). * RCC spreads primarily via the **hematogenous route** (unusual for carcinomas), often invading the renal vein and extending into the Inferior Vena Cava (IVC) [2]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Osteoarticular And Connective Tissue Disease, pp. 671-672. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 492-493. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Kidney, pp. 959-961.

Question 614: CEA is a marker for all except?

A. Carcinoma of the pancreas
B. Carcinoma of the colon
C. Carcinoma of the lung
D. Carcinoma of the prostate (Correct Answer)

Explanation: **Explanation:** **Carcinoembryonic Antigen (CEA)** is a complex oncofetal glycoprotein normally produced during fetal development in the gastrointestinal tract, pancreas, and liver. In adults, its expression is normally very low, but it becomes significantly elevated in various **adenocarcinomas**, particularly those of endodermal origin [2]. **Why Option D is the correct answer:** **Carcinoma of the prostate** is the correct answer because its primary and most specific tumor marker is **Prostate-Specific Antigen (PSA)** [1]. CEA is generally not elevated in prostate cancer, as this malignancy does not typically express oncofetal antigens associated with the endodermal/GI lineage [2]. **Analysis of other options:** * **Carcinoma of the colon (Option B):** CEA is the classic marker for colorectal cancer [2]. While not used for screening (due to low specificity), it is the "gold standard" for monitoring recurrence and response to therapy. * **Carcinoma of the pancreas (Option A):** CEA is frequently elevated in pancreatic cancer, though **CA 19-9** is a more specific marker for this site [2]. * **Carcinoma of the lung (Option C):** CEA is often elevated in non-small cell lung cancer (NSCLC), particularly **adenocarcinoma** of the lung. **NEET-PG High-Yield Pearls:** 1. **Non-specific elevations:** CEA can also be elevated in non-neoplastic conditions like **smoking**, alcoholic cirrhosis, ulcerative colitis, and pancreatitis [2]. 2. **Clinical Use:** The primary role of CEA is **post-operative surveillance** to detect early recurrence of colorectal carcinoma. 3. **Other CEA-positive tumors:** Medullary carcinoma of the thyroid, breast cancer, and gastric cancer [2]. 4. **Prostate Marker Tip:** For NEET-PG, remember: **PSA** (Screening/Monitoring) [1], **Prostatic Acid Phosphatase** (Bone metastasis), and **PCA3** (Urine marker). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lower Urinary Tract and Male Genital System, pp. 992-994. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, p. 346.

Question 615: Chronic, increased exposure to ionizing radiation results in damage to cellular DNA. As a consequence, a protein that normally arrests the cell in the G1 phase of the cell cycle is absent. Subsequently, the cell transforms and acquires unregulated growth. The absent protein is most likely the product of which of the following genes?

A. RAS
B. VHL
C. p53 (Correct Answer)
D. MYC

Explanation: **Explanation:** The correct answer is **p53 (Option C)**. **Mechanism:** The **TP53 gene**, often called the "Guardian of the Genome," encodes the p53 protein. In response to DNA damage (such as that caused by ionizing radiation), p53 levels rise [1]. It acts as a transcription factor for **p21**, a Cyclin-Dependent Kinase Inhibitor (CDKI) [1]. p21 inhibits the Cyclin E/CDK2 complex, preventing the phosphorylation of the Retinoblastoma (Rb) protein. This results in **cell cycle arrest in the G1 phase**, allowing time for DNA repair [2]. If repair fails, p53 induces apoptosis via the BAX/BAK pathway [3]. Absence or mutation of p53 allows cells with damaged DNA to enter the S-phase, leading to unregulated growth and malignant transformation [1]. **Why other options are incorrect:** * **RAS (Option A):** This is a proto-oncogene. Mutations lead to a "permanent on" state of signal transduction for growth, but it does not primarily regulate the G1 checkpoint. * **VHL (Option B):** The Von Hippel-Lindau gene is a tumor suppressor involved in the degradation of Hypoxia-Inducible Factor (HIF-1α). Its absence leads to highly vascular tumors (e.g., Renal Cell Carcinoma), not G1 arrest. * **MYC (Option D):** A proto-oncogene that acts as a transcription factor promoting cell proliferation. Overexpression (e.g., Burkitt Lymphoma) drives the cell cycle forward rather than arresting it. **High-Yield Clinical Pearls for NEET-PG:** * **Most Common Mutation:** TP53 is the most frequently mutated gene in human cancers (>50%) [4]. * **Li-Fraumeni Syndrome:** A germline mutation in TP53 leading to multiple early-onset cancers (SBLA syndrome: Sarcoma, Breast, Leukemia, Adrenal). * **Quiescence vs. Senescence:** p53-mediated G1 arrest is "Quiescence" (temporary), whereas permanent arrest is "Senescence" [3]. * **HPV Connection:** The E6 protein of Human Papillomavirus (HPV) degrades p53, facilitating cervical carcinogenesis. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 302-303. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 227-228. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 303-304. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 301-302.

Question 616: Which of the following conditions is NOT associated with an increased risk of malignancy?

A. Cholelithiasis
B. Ulcerative colitis
C. Bronchiectasis (Correct Answer)
D. Paget's disease

Explanation: **Explanation:** The correct answer is **Bronchiectasis**. This question tests the concept of **Precancerous Conditions**, which are clinical states associated with a significantly higher risk of developing cancer [1]. **Why Bronchiectasis is the correct answer:** Bronchiectasis is a chronic obstructive airway disease characterized by permanent dilation of bronchi due to destruction of muscle and elastic tissue. While it involves chronic inflammation and scarring, it is **not** considered a premalignant condition. In contrast, chronic inflammation in other organs often leads to metaplasia and subsequent dysplasia, but the pathology of bronchiectasis typically results in fibrosis or secondary amyloidosis rather than malignant transformation. **Analysis of incorrect options:** * **Cholelithiasis:** Chronic gallstones cause persistent irritation of the gallbladder wall, leading to chronic cholecystitis. This is a well-established risk factor for **Gallbladder Carcinoma** [3]. * **Ulcerative Colitis:** Long-standing inflammatory bowel disease (IBD) leads to constant mucosal repair and oxidative stress [4]. This significantly increases the risk of **Colorectal Cancer**, necessitating regular surveillance colonoscopies. * **Paget’s Disease of Bone:** This condition involves disordered bone remodeling. In approximately 1% of cases (higher in extensive disease), it can transform into **Osteosarcoma**. **High-Yield Clinical Pearls for NEET-PG:** * **Other Precancerous Conditions:** Actinic keratosis (Squamous cell carcinoma), Barrett’s esophagus (Adenocarcinoma), Atrophic gastritis (Gastric cancer), and Xeroderma pigmentosum (Skin cancers) [2]. * **Rule of Thumb:** Chronic inflammation + Persistent cell regeneration = Increased risk of DNA mutation and malignancy [1]. * **Exception:** While most chronic inflammations are risks, **Bronchiectasis** and **Peptic Ulcer Disease** (specifically duodenal ulcers) are generally not considered direct precursors to malignancy. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 286-287. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 222-223. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 884-886. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Gastrointestinal Tract, pp. 807-809.

Question 617: Which of the following is NOT a specific tumor marker?

A. CD 99
B. HMB 45
C. beta-globulin
D. CEA (Correct Answer)

Explanation: **Explanation:** The question asks for the marker that is **NOT** a specific tumor marker. In oncology, "specificity" refers to a marker's ability to pinpoint a particular cell type or malignancy. **Why CEA is the Correct Answer:** **Carcinoembryonic Antigen (CEA)** is a classic example of an **oncofetal antigen** [1]. It is highly **non-specific** because it can be elevated in a wide variety of conditions. While most commonly associated with colorectal carcinoma, it is also elevated in cancers of the pancreas, stomach, breast, and lung [2]. Crucially, it also rises in non-neoplastic conditions like heavy smoking, cirrhosis, and inflammatory bowel disease [1]. Therefore, CEA is primarily used for **monitoring treatment response and detecting recurrence**, rather than initial diagnosis [1]. **Analysis of Incorrect Options:** * **CD 99 (MIC2):** A highly specific marker for **Ewing’s Sarcoma** and Primitive Neuroectodermal Tumors (PNET). It shows a characteristic membranous staining pattern. * **HMB 45:** A specific monoclonal antibody used to identify **Melanoma**. It reacts against gp100, a protein found in melanosomes. * **Beta-globulin:** While broad, in the context of specific diagnostic pathology (like Beta-2 Microglobulin), it serves as a specific prognostic marker for **Multiple Myeloma** and certain lymphomas. **NEET-PG High-Yield Pearls:** * **Most specific marker for Prostate Cancer:** PSA (though it is organ-specific, not cancer-specific) [2]. * **Calretinin:** Most specific marker for **Mesothelioma**. * **Alpha-fetoprotein (AFP):** Elevated in Hepatocellular Carcinoma (HCC) and Yolk Sac Tumors [2]. * **S-100:** A sensitive but non-specific marker for melanoma, neural tumors, and chondroid tumors. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 319-320. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, p. 346.

Question 618: All of the following are DNA oncogenic viruses except?

A. Epstein-Barr virus (EBV)
B. Hepatitis B virus (HBV)
C. Human T-lymphotropic virus 1 (HTLV-1) (Correct Answer)
D. Human herpesvirus 8 (HHV-8)

Explanation: **Explanation:** The core concept tested here is the classification of oncogenic viruses based on their genetic material (DNA vs. RNA) [1]. **Why HTLV-1 is the correct answer:** Human T-lymphotropic virus 1 (HTLV-1) is an **RNA Retrovirus**. It is the only RNA virus directly linked to human cancer (specifically Adult T-cell Leukemia/Lymphoma or ATLL) [1], [3]. It utilizes the *tax* gene to stimulate T-cell proliferation and inhibit DNA repair, leading to oncogenesis [3]. Since the question asks for the exception among DNA viruses, HTLV-1 is the correct choice. **Analysis of Incorrect Options (DNA Oncogenic Viruses):** * **Epstein-Barr virus (EBV):** A double-stranded DNA virus (HHV-4) associated with Burkitt lymphoma, Nasopharyngeal carcinoma, and Hodgkin lymphoma [1], [2]. * **Hepatitis B virus (HBV):** A partially double-stranded DNA virus. It causes hepatocellular carcinoma primarily through chronic inflammation and the oncogenic effects of the HBx protein [2]. * **Human herpesvirus 8 (HHV-8):** Also known as Kaposi Sarcoma-associated Herpesvirus (KSHV), it is a DNA virus responsible for Kaposi sarcoma and Primary effusion lymphoma [1], [2]. **High-Yield Clinical Pearls for NEET-PG:** * **DNA Oncogenic Viruses:** Remember the mnemonic **"HHHAPy"** — **H**PV (16, 18), **H**BV, **H**HV-8, **A**denovirus (in animals), and **P**olyomavirus (Merkel cell virus). EBV is also a key member [1]. * **RNA Oncogenic Viruses:** Primarily **HTLV-1**. Note that Hepatitis C Virus (HCV) is an RNA virus associated with cancer, but it lacks a viral oncogene and causes cancer indirectly through chronic injury [2]. * **Key Association:** HTLV-1 is endemic in Japan and the Caribbean; look for "flower cells" on a peripheral smear in ATLL cases [1]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 219-220. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 335-337. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, p. 334.

Question 619: A child presents with an abdominal mass. Biopsy showed a triphasic tumor. Which of the following is a characteristic feature of this tumor?

A. MYCN amplification
B. C-MYC overexpression
C. WT1 mutation (Correct Answer)
D. RB deletion

Explanation: The clinical presentation of an abdominal mass in a child, combined with the histological finding of a **triphasic tumor**, is pathognomonic for **Wilms Tumor (Nephroblastoma)** [1]. A triphasic pattern consists of three components: blastemal (sheets of small blue cells), stromal (fibrocytic or myxoid), and epithelial (tubules or glomeruli) [1]. **Why WT1 mutation is correct:** Wilms tumor is associated with genetic alterations on chromosome 11. The **WT1 gene** (located at 11p13) is critical for normal renal development [2]. Mutations or deletions in WT1 are found in approximately 10-20% of sporadic Wilms tumors and are classically associated with syndromic cases like **WAGR syndrome** (Wilms tumor, Aniridia, Genitourinary anomalies, and Retardation) and **Denys-Drash syndrome** [2]. **Analysis of Incorrect Options:** * **A. MYCN amplification:** This is the hallmark prognostic marker for **Neuroblastoma**, the most common extracranial solid tumor in children [3]. While it also presents as an abdominal mass, it does not show a triphasic histology. * **B. C-MYC overexpression:** This is associated with **Burkitt Lymphoma** (t(8;14)), characterized by a "starry-sky" appearance on histology. * **C. RB deletion:** Loss of the RB1 gene (13q14) is associated with **Retinoblastoma** and Osteosarcoma, not Wilms tumor. **NEET-PG High-Yield Pearls:** * **Most common** primary renal tumor of childhood. * **Beckwith-Wiedemann Syndrome (BWS):** Associated with WT2 mutation (11p15.5), macroglossia, and hemihypertrophy. * **Nephrogenic rests:** Precursor lesions often found in the renal parenchyma adjacent to the tumor [1]. * **Prognosis:** Generally excellent, but the presence of **anaplasia** (TP53 mutation) indicates a poor prognosis and resistance to chemotherapy. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, pp. 488-490. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, pp. 487-488. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, pp. 486-487.

Question 620: Which of the following proteins is known as the "guardian of the genome"?

A. p53 (Correct Answer)
B. Mdm2
C. pl4
D. ATM

Explanation: **Explanation:** **p53 (Option A)** is known as the **"Guardian of the Genome"** because of its critical role in maintaining genomic stability [1]. It is a tumor suppressor protein encoded by the *TP53* gene on chromosome 17p [1]. When DNA damage occurs, p53 levels rise and trigger one of three pathways: 1. **Quiescence:** Temporary cell cycle arrest (at the G1-S checkpoint) via p21 induction to allow for DNA repair [1]. 2. **Senescence:** Permanent cell cycle arrest [1]. 3. **Apoptosis:** Programmed cell death via BAX (pro-apoptotic) if the damage is irreparable [1]. By preventing the replication of cells with mutated DNA, p53 prevents the propagation of oncogenic mutations [1]. **Analysis of Incorrect Options:** * **Mdm2 (Option B):** This is a negative regulator of p53. It acts as an E3 ubiquitin ligase that targets p53 for degradation in the proteasome. Overexpression of Mdm2 can lead to functional inactivation of p53, promoting cancer. * **p14/ARF (Option C):** This protein acts as a tumor suppressor by inhibiting Mdm2, thereby stabilizing and increasing p53 levels. * **ATM (Option D):** Ataxia-Telangiectasia Mutated (ATM) is a protein kinase that senses double-stranded DNA breaks. It phosphorylates p53, activating it. While crucial for the DNA damage response, it is not the "guardian" itself. **High-Yield Clinical Pearls for NEET-PG:** * **Li-Fraumeni Syndrome:** A germline mutation in *TP53* leading to a high risk of multiple diverse tumors (SBLA: Sarcoma, Breast, Leukemia, Adrenal gland). * **Most Common Mutation:** *TP53* is the most frequently mutated gene in human cancers (>50%) [1]. * **HPV Connection:** The E6 oncoprotein of High-Risk HPV (types 16, 18) binds to and degrades p53. [2] is also used to support the mechanism of p21 and GADD45 involvement in DNA repair. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 301-304. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 227-228.

Practice by Chapter

Nomenclature and Classification of Tumors

Practice Questions

Characteristics of Benign and Malignant Neoplasms

Practice Questions

Molecular Basis of Cancer

Practice Questions

Carcinogenesis and Carcinogens

Practice Questions

Tumor Progression and Metastasis

Practice Questions

Tumor Markers

Practice Questions

Paraneoplastic Syndromes

Practice Questions

Genetic Basis of Cancer

Practice Questions

Tumor Immunity

Practice Questions

Cancer Epidemiology and Prevention

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Neoplasia — MCQs

Neoplasia — MCQs

On this page

Practice by Chapter

Want unlimited practice?